Tetadex Sulfobutyl Aethe Sodium Cas 182410-00-0

Tetadex Sulfobutyl Aethe Sodium Cas 182410-00-0

Tetadex sulfobutyl Aethe sodium cas 182410-00-0 est CyclodExtrin derivative et a Sina Deli scriptor nova genus pharmaceutical excipients.

Mitte Inquisitionem

depictio producti

Tetadex Sulfobutyl Aethe San Sina Cas 182410-00-0 est a Sina Deli scriptor novum genus anionic altum solutum Cyclodextrin derivationes. Tetadex Sulfobutyl Aethe Sodium Cas non 182410-00-0 est sodium sal produci cum Retadex est alkaline per 1,4-Butanesulfonic Acidum lactone sub alkaline conditionibus. Est anion, altus aquam, solutum Retadex inde. Potest solebat ut solubilizer, madefecisset agente, chelaing agente (complexing agente) et polydat masking agente.


Tetadex Sulfobutyl Aethe Sodium Cas 182410-00-0 est in iniectio, oris, nasi et oculus medicina. Hoc est specialis affinitate et inclusione ad NITROGENIUM medicinae. Augmentum medicamento scriptor stabilitatem, solubility, salus (includit medicamento moleculis ad formare non-covalent). Redigendum renum toxicity, otium medicamento hemolysis. Release rate control medicamento, operiet mala odor. Noster Company producit Tetadex Sulfobutyl Aethe Sodium Cas non 182410-00-0 et hydroxypropyl βETADEX CAS 128446-35-5 omnes possunt providere liberum samples


Tetadex Sulfobutyl Aethe Sodium Cas non 182410-00-0 Signa

[Cas non]: 128410-00-0
[Molecular formula] C42H70-no35• (c4H8Sic3Et) n
[Specification]: 500g / peram; 1KG / peram; 10Kg / pera / tympanum; aut ut vestri postulationem
[Category]: Pharmaceutical excipients
[Repono]: sigillum conservationem.
[Period validitatem]: XXXVI mensibus



Hot Tags: Tetadex Sulfobutyl Aethe Sodium Cas 182410-00-0, Manufacturers, Suspendisse, Sina, Factory, mole, liberum sample, in Sina, in Stock, Wholesale, Buy

Related Categoria

Mitte Inquisitionem

Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept